DEVRIAZ Trademark

Trademark Overview

On Monday, August 7, 2017, a trademark application was filed for DEVRIAZ with the United States Patent and Trademark Office. The USPTO has given the DEVRIAZ trademark a serial number of 87558420. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 8, 2021. This trademark is owned by Pfizer Inc.. The DEVRIAZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
devriaz

General Information

Serial Number87558420
Word MarkDEVRIAZ
Filing DateMonday, August 7, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 8, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 7, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 10, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, February 8, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 8, 2021ABANDONMENT - NO USE STATEMENT FILED
Friday, May 15, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 14, 2020EXTENSION 5 GRANTED
Wednesday, May 6, 2020EXTENSION 5 FILED
Thursday, May 14, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, May 6, 2020TEAS EXTENSION RECEIVED
Monday, May 4, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, May 4, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 4, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, May 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, May 4, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, December 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 12, 2019EXTENSION 4 GRANTED
Thursday, December 12, 2019EXTENSION 4 FILED
Thursday, December 12, 2019TEAS EXTENSION RECEIVED
Wednesday, June 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 24, 2019EXTENSION 3 GRANTED
Monday, June 24, 2019EXTENSION 3 FILED
Monday, June 24, 2019TEAS EXTENSION RECEIVED
Wednesday, December 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 10, 2018EXTENSION 2 GRANTED
Monday, December 10, 2018EXTENSION 2 FILED
Monday, December 10, 2018TEAS EXTENSION RECEIVED
Thursday, June 14, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 12, 2018EXTENSION 1 GRANTED
Tuesday, June 12, 2018EXTENSION 1 FILED
Tuesday, June 12, 2018TEAS EXTENSION RECEIVED
Tuesday, January 2, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 7, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 7, 2017PUBLISHED FOR OPPOSITION
Wednesday, October 18, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, September 18, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, September 16, 2017ASSIGNED TO EXAMINER
Thursday, August 10, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, August 10, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

devriaz preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological